Cargando…
Aptamer‐SH2 superbinder‐based targeted therapy for pancreatic ductal adenocarcinoma
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid tumors with a 5‐year survival rate of less than 10% and a median survival of 6 months after diagnosis. Numerous targeted agents have been developed and evaluated to improve the survival benefit in patient...
Autores principales: | Liu, An‐Dong, Zhou, Jie, Bi, Xiao‐Yang, Hou, Guo‐Qing, Li, Shawn Shun‐Cheng, Chen, Qing, Xu, Hui, Cao, Xuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908048/ https://www.ncbi.nlm.nih.gov/pubmed/33783993 http://dx.doi.org/10.1002/ctm2.337 |
Ejemplares similares
-
Blockade of phosphotyrosine pathways suggesting SH2 superbinder as a novel therapy for pulmonary fibrosis
por: Wang, Meng, et al.
Publicado: (2022) -
(Arg)(9)-SH2 superbinder: a novel promising anticancer therapy to melanoma by blocking phosphotyrosine signaling
por: Liu, An-dong, et al.
Publicado: (2018) -
Identification and characterization of a large family of superbinding bacterial SH2 domains
por: Kaneko, Tomonori, et al.
Publicado: (2018) -
Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma
por: Li, Q., et al.
Publicado: (2020) -
A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma
por: Clawson, Gary A., et al.
Publicado: (2017)